Joshua Johnston, OD
Optometrist · Atlanta, GANPI 1013929520
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $707,595 of the $992,980 with a category attached, or 71.3%. 34 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 31.6% of the total. 2025 is the largest year on record at $252,314, 4.6 times the $55,335 reported in 2019. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,631 payments — averaging $608.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$314K
- AbbVie$212K
- Bausch & Lomb Americas Inc.$126K
- Tarsus Pharmaceuticals, Inc.$108K
- Oyster Point Pharma, Inc.$47K
- Sight Sciences, Inc.$46K
- plus $140K from 28 others
Across 4 payments — averaging $922.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$4K
What the payments were for
- Consulting fees$162,52816%
- Speaking & faculty fees$707,59571%
- Travel & lodging$89,7459%
- Food & beverage$32,9403%
- Education$1720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$307,897
- MIEBO$121,147
- XIIDRA$102,508
- XDEMVY$96,879
- VUITY$59,319
- RESTASIS$58,534
- RESTASIS MULTIDOSE$46,111
- TYRVAYA$43,992
- VEVYE$41,111
- TearCare SmartLid$20,491
- TEARCARE(TM) (2.2) SYSTEM KIT$20,491
- TEARCARE SYSTEM$20,103
- TRYPTYR$16,751
- Oxervate$16,283
- Lacrifill$8,400
- EYSUVIS$8,073
- TearCare$4,415
- Prokera$2,818
- AmnioGraft$2,818
- VYZULTA$2,525
How this compares
$992,980 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 168 | $202,028 |
| CequaCyclosporine | 99 | $104,579 |
| XiidraLifitegrast | 56 | $80,739 |
| XdemvyLotilaner | 39 | $72,639 |
| MieboPerfluorohexyloctane/Pf | 45 | $34,121 |
| Cyclosporine | 56 | $33,921 |
| TyrvayaVarenicline Tartrate | 25 | $16,242 |
| Lotemax SmLoteprednol Etabonate | 55 | $13,804 |
| LumiganBimatoprost | 20 | $12,027 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $7,578 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $6,449 |
| EysuvisLoteprednol Etabonate | 13 | $6,408 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $5,224 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 101 | $3,892 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $3,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $212,143 | $220,504206 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $126,080 | $114,859101 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $314,193 | $104,57999 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $107,994 | $72,63939 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $46,553 | $16,24225 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $48 | $13,80455 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $39 | $7,57812 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $8,329 | $6,40813 claims |
| AlconSimbrinza | $23,440 | $5,22424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Atlanta
- Amber ZaunbrecherAtlanta$99K
- Emily LoveAtlanta$35K
- Carla AndersonAtlanta$29K
- Sarah FlanaganAtlanta$21K
- Anisha HajiAtlanta$19K
- Anar MauryaAtlanta$18K
- Jonathan ChenAtlanta$15K
- Heer VaishnavAtlanta$14K
- Mohammad AljabiAtlanta$13K
- Soo Jung LeeAtlanta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.